Mission Statement, Vision, & Core Values (2026) of Ono Pharmaceutical Co., Ltd.

Step into the remarkable story of Ono Pharmaceutical Co., Ltd. (4528.T), a company founded in 1717 in Osaka that has cultivated three centuries of innovation in oncology, immunology and neurology while championing a patient-centric mission-'Dedicated to the Fight against Disease and Pain'-and a rallying slogan, 'BREAK THROUGH - Embrace the Challenge with ONO'; from establishing ONO PHARMA USA in 1998 to committing to long-range sustainability through ECO VISION 2050, Ono pairs a resolute Quality Global Policy with a vision to be 'passionate challengers' by 2031 (2031) and beyond, uniting integrity, dignity, and patient-first core values to accelerate drug discovery with top scientists and digital tools and to expand as a specialty pharma competing on the world stage-read on to discover how these concrete milestones, governance priorities, and measurable timelines translate into real-world impact for patients and global healthcare.

Ono Pharmaceutical Co., Ltd. (4528.T) - Intro

• Founded: 1717 (Osaka, Japan)
• Primary therapeutic focuses: Oncology, Immunology, Neurology
• Global subsidiary: ONO PHARMA USA established 1998 (international clinical & commercial activities)
• Sustainability framework: ECO VISION 2050 - aims for decarbonization and reduced environmental impact

• Quality pillars: Safety, Efficacy, Reliability
• Global QA footprint: centralized quality management + regional quality offices
• Clinical emphasis: late-stage oncology assets and immuno-oncology collaborations

• Innovation-first R&D: high allocation of revenue to R&D to drive first-in-class and best-in-class therapies.
• Patient-centricity: clinical programs prioritized by unmet medical need and real-world impact.
• Global collaboration: licensing, co-development and royalty-based partnerships to extend reach (notably oncology alliances).
• Sustainability & governance: ECO VISION 2050 targets, corporate governance reforms, and transparent reporting on ESG metrics.

• Core revenue drivers include milestone and royalty income from in-licensed/co-developed oncology therapies and growing proprietary pipeline assets advancing into late-stage trials.
• High R&D intensity supports pipeline breadth - multiple assets in clinical development across oncology and immunology.
• International expansion via ONO PHARMA USA (est. 1998) and regional affiliates supports global trials, regulatory filings and commercialization pathways.

Ono Pharmaceutical Co., Ltd. (4528.T) - Overview

• Patient-centric drug development: prioritizing therapies that materially improve quality of life for patients with high unmet needs (oncology, immunology, pain management).
• Collaborative innovation: partnering with academic institutions and biotech to accelerate discovery and translational research.
• Global specialty-pharma ambition: expanding international footprint to commercialize specialty medicines worldwide.
• Digital and social impact: deploying digital health tools and initiatives to address healthcare access and population health challenges.
• Governance and transparency: strengthening management systems and compliance to support multinational operations.

• Accelerating discovery: expanding preclinical capacities and computational drug-discovery collaborations to reduce time-to-clinic; tracked by number of IND filings per year and preclinical candidate throughput.
• Patient outcomes focus: post-marketing real-world evidence (RWE) programs and patient-reported outcome (PRO) studies to measure QoL improvements.
• Global commercialization: licensing and co-promotion deals to enter new markets, measured by percentage of sales from outside Japan (growing share targeted).
• Digital health integration: pilots in telemedicine, remote monitoring, and AI-enabled trial optimization to improve trial enrollment and data quality.
• Governance: enhancing board governance, compliance frameworks, and ESG reporting to support cross-border operations and investor confidence.

• Partnerships with academic centers and biotech firms to co-develop oncology and immunology candidates - increasing external R&D productivity and leveraging specialized expertise.
• Investment in RWE and digital tools to shorten development cycles and demonstrate real-world patient benefit, supporting regulatory and payer engagement.
• Selective M&A and licensing to build therapeutic-area depth and expand geographic reach, with a focus on specialty segments where Ono can be competitive globally.

Ono Pharmaceutical Co., Ltd. (4528.T) - Mission Statement

• Be the most passionate champion against disease and pain, working hand-in-hand with patients, families, and healthcare providers.
• Act as a world-changing team that brings together wisdom, heart, aspirations, and power to meet unprecedented medical challenges.
• Rise with ingenuity and perseverance to confront greater scientific and societal obstacles.
• Carry out business with dignity and pride, serving as a bringer of hope for those awaiting solutions.
• Contribute to a sustainable society through responsible business activities, in line with the long-term vision for 2031.

• Prioritizing oncology and immune-oncology programs, leveraging historic partnerships to fund and accelerate discovery.
• Investing a high proportion of revenue back into R&D to sustain a pipeline of first-in-class and best-in-class candidates.
• Pursuing patient-centered development pathways - early access programs, real-world evidence generation, and collaborative trials.
• Embedding sustainability and corporate responsibility targets into long-term planning toward the 2031 vision.

Ono Pharmaceutical Co., Ltd. (4528.T) - Vision Statement

• World-changing ambition: prioritize high-barrier, high-impact therapeutic challenges.
• Ingenuity and perseverance: sustain long-term R&D investments to overcome complex scientific hurdles.
• Dignity and hope: be the dependable partner for patients, clinicians, and healthcare systems.
• Quality and safety: maintain robust manufacturing and pharmacovigilance standards.
• Patient-centric excellence: ensure patient rights, access, and experience guide development and commercialization.
• Integrity and accountability: keep transparent governance, traceability, and compliance across operations.

• R&D intensity: sustain a target R&D-to-revenue ratio that funds late-stage trials and novel discovery (current example: ~21% of revenue).
• Quality & safety: maintain zero-tolerance for GMP non-compliance; track batch-release rates and adverse event reporting timelines.
• Patient-centric measures: patient-reported outcome (PRO) inclusion rates in pivotal trials; increase access programs year-over-year.
• Integrity & transparency: percentage of third-party audits with no major findings; timely disclosure of clinical and financial results.

• Strategic partnerships: licensing and co-development to accelerate access and spread development risk.
• Manufacturing excellence: capacity investments to ensure supply reliability for key products and clinical supplies.
• Portfolio focus: prioritization framework that channels resources into programs with clear unmet need and regulatory pathways.
• Stakeholder engagement: enhanced communications with patients, physicians, and investors to align expectations and measure impact.